Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

BACKGROUND: VLA1553 is a live-attenuated vaccine candidate for active immunisation and prevention of disease caused by chikungunya virus. We report safety and immunogenicity data up to day 180 after vaccination with VLA1553. METHODS: This double-blind, multicentre, randomised, phase 3 trial was done...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Martina, Narciso-Abraham, Marivic, Hadl, Sandra, McMahon, Robert, Toepfer, Sebastian, Fuchs, Ulrike, Hochreiter, Romana, Bitzer, Annegret, Kosulin, Karin, Larcher-Senn, Julian, Mader, Robert, Dubischar, Katrin, Zoihsl, Oliver, Jaramillo, Juan-Carlos, Eder-Lingelbach, Susanne, Buerger, Vera, Wressnigg, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314240/
https://www.ncbi.nlm.nih.gov/pubmed/37321235
http://dx.doi.org/10.1016/S0140-6736(23)00641-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314240/
https://www.ncbi.nlm.nih.gov/pubmed/37321235
http://dx.doi.org/10.1016/S0140-6736(23)00641-4

Ejemplares similares